The Global Alzheimer’s Platform Foundation (GAP) and the Alzheimer’s Disease Data Initiative (AD Data Initiative) have released the Bio‑Hermes‑001 dataset — described as the most comprehensive biomarker dataset in Alzheimer’s research history.
The release of Bio‑Hermes‑001 marks a pivotal moment in Alzheimer’s research: a first‑of‑its‑kind dataset blending biomarker, cognitive, retinal, and speech data across a deeply diverse cohort.
Now available to scientists worldwide, it promises to accelerate validation of emerging diagnostic tools and spur progress toward earlier diagnosis — potentially benefiting underserved communities and transforming care pathways.
What Makes Bio‑Hermes‑001 Groundbreaking?
- Contains over 80,000 blood and digital test results from diagnostic tools including digital cognitive tests, retinal exams, speech analysis, and traditional PET imaging.
- Participants are highly diverse, with 24% representing traditionally understudied communities, and include individuals who are cognitively normal, with mild cognitive impairment (MCI), or mild Alzheimer’s disease.
- It provides side‑by‑side performance comparisons of dozens of Alzheimer’s diagnostic methods.
Why This Matters
- Researchers and developers can now use this rich dataset to validate and advance new blood‑based and digital diagnostic tests.
- Portions of the dataset have already supported an FDA application for the first blood‑based in vitro diagnostic (IVD) for Alzheimer’s disease.
How to Access the Data
- The dataset is available publicly via the AD Workbench.
- Researchers can request access starting August 1, 2025, through the AD Discovery Portal on AD Workbench.
